home / stock / ruby / ruby news


RUBY News and Press, Rubius Therapeutics Inc. From 03/15/21

Stock Information

Company Name: Rubius Therapeutics Inc.
Stock Symbol: RUBY
Market: OTC
Website: rubiustx.com

Menu

RUBY RUBY Quote RUBY Short RUBY News RUBY Articles RUBY Message Board
Get RUBY Alerts

News, Short Squeeze, Breakout and More Instantly...

RUBY - Eli Lilly, Magnite leads the premarket losers' pack

Torchlight Energy Resources (TRCH) -15% on business combination timingRubius Therapeutics (RUBY) -14% on initial data for RTX-240 in solid tumorsEntera Bio (ENTX) -13%.Nova LifeStyle (NVFY) -12%.NLS Pharmaceutics (NLSP) -12%.Eli Lilly and Company (LLY) -7% after ...

RUBY - Rubius Therapeutics falls on initial data for RTX-240 in solid tumors

Rubius Therapeutics (RUBY) has reversed early gains in premarket hours after the company reported initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors. The stock is trading ~14.1% lower currently.“We believe these data provi...

RUBY - Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

RTX-240 Generated Partial Responses in Metastatic Anal Cancer and Metastatic Uveal Melanoma Patients; No DLTs or Related Grade 3/4 Adverse Events RTX-240 Promoted Trafficking of NK and T Cells into Tumor Microenvironment Initial Clinical Data Provide Evidence of Broa...

RUBY - NXPI, TPIC, EOLS and UBX among after-hours movers

Gainers: [[RUBY]] +16.8%. [[SALM]] +7.5%. [[NXPI]] +5%. [[CHMA]] +3.5%. [[UBX]] +2.7%.Losers: [[CLPS]] -4.2%. [[AMTX]] -3.9%. [[VRAY]] -3.2%. [[TPIC]] -2.8%. [[EOLS]] -2.5%. For further details see: NXPI, TPIC, EOLS and UBX among after-hours movers

RUBY - Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., March 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announc...

RUBY - Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting

CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announce...

RUBY - Second Sight Medical Products, OpGen leads healthcare gainers; Soleno Therapeutics, AnaptysBio among major losers

Gainers: Second Sight Medical Products (EYES) +92%, OpGen (OPGN) +79%, Anchiano Therapeutics (ANCN) +64%, Jaguar Health (JAGX) +29%, Idera Pharmaceuticals (IDRA) +22%.Losers: Soleno Therapeutics (SLNO) -44%, AnaptysBio (ANAB) -34%, T...

RUBY - Rubius Therapeutics (RUBY) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow

The following slide deck was published by Rubius Therapeutics, Inc. in conjunction with this event. For further details see: Rubius Therapeutics (RUBY) Presents At SVB Leerink 10th Annual Global Healthcare Conference - Slideshow

RUBY - FSR, OCGN, VST and ZYXI among midday movers

Gainers: Xtant Medical (XTNT) +189%.Intrusion (INTZ) +33%.Armstrong Flooring (AFI) +28%.Just Energy Group (JE) +28%.AMC Networks (AMCX) +26%.Applied UV (AUVI) +24%.Fisker (FSR) +21%.Ocugen (OCGN) +20%.Select Medical (SEM) +19%.Rubius Therapeutics (RUBY) +19%.Losers: Tricid...

RUBY - Xtant Medical, Sensus Healthcare leads healthcare gainers; Tricida, Recro Pharma among major losers

Gainers: Xtant Medical (XTNT) +54%, Sensus Healthcare (SRTS) +34%, Rubius Therapeutics (RUBY) +23%, Select Medical (SEM) +18%, Dynavax Technologies (DVAX) +18%.Losers: Tricida (TCDA) -32%, Recro Pharma (REPH) -27%, Zynex (ZYXI) -17%,...

Previous 10 Next 10